Abstract

Introduction: Serum level of high sensitivity C-reactive protein (hs-CRP), as an inflammatory marker, can play a role in development of metabolic syndrome in obese individuals. Objectives: This study aimed to determine serum concentration of hs-CRP in obese patients with metabolic syndrome and determine the association of this factor with factors involved in the progression of metabolic syndrome. Patients and Methods: In this study, samples were selected by convenient method from obese patients, admitted to Kashani and Hajar hospitals (Shahrekord, Iran). First, based on NCEP-ATPIIIdefined metabolic syndrome, parameters of metabolic syndrome and serum levels of vitamin D were measured and a questionnaire containing demographics was completed for each participant. Accordingly, the samples (n=192) were divided into two identical groups; obese individuals without metabolic syndrome (controls) and obese individuals with metabolic syndrome (case group). HsCRP levels were measured in both groups. Results: Serum level of hs-CRP in the case group was 17.58±1.40 µg/mL and in the control group was 9.04±1.26 µg/mL, which was significantly higher in the case group than the control group (P 0.05). Conclusion: Hs-CRP can be used for prognosis and early detection of patients at risk of metabolic syndrome.

Highlights

  • Serum level of high sensitivity C-reactive protein, as an inflammatory marker, can play a role in development of metabolic syndrome in obese individuals

  • Mean of serum level of high sensitivity C-reactive protein (hs-CRP) in the case group was 17.58 ± 1.40 μg/mL and in the control group was 9.04 ± 1.26 μg/mL, which was significantly higher in the case group than the control group (P < 0.001) with a maximum level of hs-CRP at 36.4 μg/mL and minimum at 0.1 μg/mL

  • Hs-CRP was significantly associated with weight in the control group (r=-0.31; P < 0.001), but there was no significant association in the case group (P > 0.05)

Read more

Summary

Introduction

Serum level of high sensitivity C-reactive protein (hs-CRP), as an inflammatory marker, can play a role in development of metabolic syndrome in obese individuals. Metabolic syndrome is a serious complication that develops following a sedentary lifestyle and poor nutrition This syndrome was first introduced in 1998 as one of the background factors contributing to cardiovascular diseases and diabetes [1] and is known by other names, including syndrome X, insulin resistance syndrome, deadly quartet, obesity-dyslipidemia syndrome, and Reaven’s syndrome [2]. According to the recent researches, it involves up to 25% of the general population [3,4] This syndrome includes a number of clinical findings and laboratory abnormalities, such as obesity (central, abdominal or visceral), increased activity of the sympathetic nervous system, hypertension, glucose intolerance, insulin resistance, compensatory hyperinsulinemia, type 2 diabetes, dyslipidemia (hypertriglyceridemia, elevated low or high density lipoprotein cholesterol [HDL-C]), fatty liver, impaired fibrinolysis, hyperuricemia, systemic inflammation, especially endothelial dysfunction and vascular inflammation [5]. Identification of other causes of this syndrome can play an important role in awareness and early detection of this syndrome and its treatment control

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.